Briani C Cocito D Campagnolo M Doneddu PE Nobile-Orazio E.

Update on therapy of chronic immune-mediated neuropathies.

Neurol Sci. 2021; https://doi.org/10.1007/s10072-020-04998-yView in Article Scopus (6) Crossref Google ScholarLehmann HC Burke D Kuwabara S.

Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment.

J Neurol Neurosurg Psychiatry. 2019; 90: 981-987https://doi.org/10.1136/jnnp-2019-320314View in Article Scopus (80) PubMed Crossref Google ScholarBrown R Ginsberg L.

POEMS syndrome: clinical update.

J Neurol. 2019; 266: 268-277https://doi.org/10.1007/s00415-018-9110-6View in Article Scopus (26) PubMed Crossref Google ScholarSvahn J Petiot P Antoine JC Vial C Delmont E Viala K et al.

Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features.

J Neurol Neurosurg Psychiatry. 2018; 89: 499-505https://doi.org/10.1136/jnnp-2017-316715View in Article Scopus (42) PubMed Crossref Google ScholarMathey EK Park SB Hughes RA Pollard JD Armati PJ Barnett MH et al.

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

J Neurol Neurosurg Psychiatry. 2015; 86: 973-985https://doi.org/10.1136/jnnp-2014-309697View in Article Scopus (250) PubMed Crossref Google ScholarHays AP Lee SSL Latov N.

Immune reactive C3d on the surface of myelin sheaths in neuropathy.

J Neuroimmunol. 1988; 18: 231-244https://doi.org/10.1016/0165-5728(88)90101-4View in Article Scopus (105) PubMed Abstract Full Text PDF Google ScholarDevaux JJ Miura Y Fukami Y Inoue T Manso C Belghazi M et al.

Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Neurology. 2016; 86: 800https://doi.org/10.1212/WNL.0000000000002418View in Article Scopus (154) PubMed Crossref Google ScholarDelmont E Brodovitch A Kouton L Allou T Beltran S Brisset M et al.

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

J Neurol. 2020; 267: 3664-3672https://doi.org/10.1007/s00415-020-10041-zView in Article Scopus (39) PubMed Crossref Google ScholarDoppler K Appeltshauser L Wilhelmi K Villmann C Dib-Hajj SD Waxman SG et al.

Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies.

J Neurol Neurosurg Psychiatry. 2015; 86https://doi.org/10.1136/jnnp-2014-309916View in Article Scopus (117) PubMed Crossref Google ScholarKoike H Nishi R Ikeda S Kawagashira Y Iijima M Katsuno M et al.

Ultrastructural mechanisms of macrophage-induced demyelination in CIDP.

Neurology. 2018; 91: 1051-1060https://doi.org/10.1212/WNL.0000000000006625View in Article Scopus (46) PubMed Crossref Google ScholarVallat JM Yuki N Sekiguchi K Kokubun N Oka N Mathis S et al.

Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies.

Neuromuscul Disord. 2017; 27: 290-293https://doi.org/10.1016/j.nmd.2016.10.008View in Article Scopus (68) PubMed Abstract Full Text Full Text PDF Google ScholarVan den Bergh PYK van Doorn PA Hadden RDM Avau B Vankrunkelsven P Allen JA et al.

European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force—second revision.

J Peripher Nerv Syst. 2021; 26: 242-268https://doi.org/10.1111/jns.12455View in Article Scopus (26) PubMed Crossref Google ScholarNeys SFH Rip J Hendriks RW Corneth OBJ.

Bruton's tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease.

Drugs. 2021; 81: 1605-1626https://doi.org/10.1007/s40265-021-01592-0View in Article Scopus (5) PubMed Crossref Google ScholarCocito D Paolasso I Antonini G Benedetti L Briani C Comi C et al.

A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Eur J Neurol. 2010; 17: 289-294https://doi.org/10.1111/j.1468-1331.2009.02802.xView in Article Scopus (96) PubMed Crossref Google ScholarLéger JM Viala K Cancalon F Maisonobe T Gruwez B Waegemans T et al.

Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients.

J Neurol Neurosurg Psychiatry. 2008; 79: 93https://doi.org/10.1136/jnnp.2007.121756View in Article Scopus (77) PubMed Crossref Google ScholarComi G Roveri L Swan A Willison H Bojar M Illa I et al.

A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.

J Neurol. 2002; 249: 1370-1377https://doi.org/10.1007/s00415-002-0808-zView in Article Scopus (133) PubMed Crossref Google ScholarAllen JA.

Chronic demyelinating polyneuropathies.

CONTINUUM: Lifelong Learning in Neurology. 2017; 23: 1310-1331https://doi.org/10.1212/con.0000000000000517View in Article Crossref Google ScholarQuerol L Crabtree M Herepath M Priedane E Viejo Viejo I Agush S et al.

Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).

J Neurol. 2021; 268: 3706-3716https://doi.org/10.1007/s00415-020-09998-8View in Article Scopus (7) PubMed Crossref Google ScholarSiddiqui K Cahalane E Keogan M Hardiman O.

Chronic ataxic neuropathy with cold agglutinins.

Neurology. 2003; 61: 1307https://doi.org/10.1212/WNL.61.9.1307View in Article Scopus (23) PubMed Crossref Google ScholarDalakas MC Rakocevic G Salajegheh M Dambrosia JM Hahn AF Raju R et al.

Placebo-controlled trial of rituximab in IgM anti–myelin-associated glycoprotein antibody demyelinating neuropathy.

Ann Neurol. 2009; 65: 286-293https://doi.org/10.1002/ana.21577View in Article Scopus (228) PubMed Crossref Google ScholarLéger JM Viala K Nicolas G Créange A Vallat JM Pouget J et al.

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Neurology. 2013; 80: 2217-2225https://doi.org/10.1212/WNL.0b013e318296e92bView in Article Scopus (132) PubMed Crossref Google ScholarQuerol L Nogales-Gadea G Rojas-Garcia R Diaz-Manera J Pardo J Ortega-Moreno A et al.

Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.

Neurology. 2014; 82: 879-886https://doi.org/10.1212/wnl.0000000000000205View in Article PubMed Crossref Google ScholarRoux T Debs R Maisonobe T Lenglet T Delorme C Louapre C et al.

Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases.

J Peripher Nerv Syst. 2018; 23: 235-240https://doi.org/10.1111/jns.12287View in Article Scopus (23) PubMed Crossref Google ScholarMurad MH Sultan S Haffar S Bazerbachi F

Methodological quality and synthesis of case series and case reports.

BMJ Evid -Based Med. 2018; 23: 60https://doi.org/10.1136/bmjebm-2017-110853View in Article Scopus (733) PubMed Crossref Google ScholarSacco JJ Botten J Macbeth F Bagust A Clark P.

The average body surface area of adult cancer patients in the UK: a multicentre retrospective study.

PLoS One. 2010; 5: e8933https://doi.org/10.1371/journal.pone.0008933View in Article Scopus (142) PubMed Crossref Google ScholarBenedetti L Garnero M Demichelis C Grandis M Briani C Beltramini S et al.

Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years.

J Neuroimmunol. 2019; 337577081https://doi.org/10.1016/j.jneuroim.2019.577081View in Article Scopus (1) PubMed Abstract Full Text Full Text PDF Google ScholarGazzola S Delmont E Franques J Boucraut J Salort-Campana E Verschueren A et al.

Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.

J Neurol Sci. 2017; 377: 144-148https://doi.org/10.1016/j.jns.2017.04.015View in Article Scopus (19) PubMed Abstract Full Text Full Text PDF Google ScholarChaudhry V Cornblath DR.

An open-label trial of rituximab (Rituxan R) in multifocal motor neuropathy.

J Peripher Nerv Syst. 2010; 15: 196-201https://doi.org/10.1111/j.1529-8027.2010.00270.xView in Article Scopus (52) PubMed Crossref Google ScholarMerkies IS van Nes SI Hanna K Hughes RA Deng C.

Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.

J Neurol Neurosurg Psychiatry. 2010; 81: 1194-1199https://doi.org/10.1136/jnnp.2009.194324View in Article Scopus (58) PubMed Crossref Google ScholarMerkies ISJ Lawo J-P Edelman JM De Bleecker JL Sommer C Robberecht W et al.

Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.

J Peripher Nerv Syst. 2017; 22: 149-152https://doi.org/10.1111/jns.12204View in Article Scopus (8) PubM